Cancer drug could tame long COVID brain fog

NCT ID NCT07388550

Not yet recruiting Symptom relief Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) Source: ClinicalTrials.gov ↗

First seen Feb 05, 2026 · Last updated May 22, 2026 · Updated 11 times

Summary

This early-stage trial tests whether a single dose of pembrolizumab, a drug used for cancer, can safely reduce long-term neurological symptoms like brain fog, headache, and dizziness after COVID-19. Fifteen adults who had COVID at least 6 months ago and still have these symptoms will receive one IV dose and be followed for 6 months. The main goal is to check safety, but researchers will also look for improvements in thinking, walking, and daily function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-ACUTE COVID-19 SYNDROME are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

POST-ACUTE COVID-19 SYNDROME